Developer docs
API playgroundTry for free, no card

Search company profiles

Cellarity

Full company profile

uuid00009ec

Namestring
Cellarity
Legal namestring
Cellarity, Inc.
Websiteurl
cellarity.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Cellarity is a clinical-stage biotechnology company founded in 2019 by Flagship Pioneering, headquartered in Cambridge, Massachusetts, with an additional office in Somerville, MA. The company is developing oral "Cell State-Correcting" small molecule therapeutics that aim to restore proper cell function by precisely regulating gene-switch mechanisms, rather than modulating single molecular targets as in conventional drug discovery. Its core technology is a multi-omics AI-powered discovery platform that integrates high-dimensional single-cell transcriptomics, surface receptor and chromatin accessibility data, and proprietary deep learning foundation models (including ToxPredictor for safety prediction and DrugReflector for active-learning phenotypic screening) to map disease biology and predict chemical interventions. The platform has demonstrated 13- to 17-fold higher recovery of phenotypically active compounds compared with industry-standard approaches.

Cellarity's lead asset, CLY-124, is a first-in-class DCN1 inhibitor and oral globin-switching therapeutic for sickle cell disease that entered a global Phase 1 clinical trial in June 2025 following FDA IND clearance, with 28-day proof-of-concept data expected in Q4 2026. The pipeline additionally includes a JAK2V617F-selective program for myelofibrosis and partnered programs with Novo Nordisk in MASH and with Pioneering Medicines in inflammatory bowel disease. The company is pre-revenue, monetizes through eventual product sales and/or licensing/royalty arrangements with pharmaceutical partners, and has raised $274 million in total funding, most recently a $121 million Series C in October 2022 led by Flagship Pioneering with participation from Kyowa Kirin and Hanwha Impact Partners.

Short descriptiontext

Cellarity is a clinical-stage biotechnology company developing oral Cell State-Correcting small molecule therapeutics through an AI-powered multi-omics and single-cell transcriptomics platform, with lead candidate CLY-124 in Phase 1 for sickle cell disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSomerville, United States
HQ citystring
Somerville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell state therapeutics, AI drug discovery, multi-omics platform, small molecule therapeutics, transcriptomics biotechnology
Industry1 code
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
Product category
Biopharmaceuticals (Cell State-Correcting Therapeutics)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical stage company developing novel therapeutics. Revenue will be generated through eventual product sales following regulatory approval, with potential licensing or partnership arrangements with pharmaceutical companies for development and commercialization rights.

cellarity.com
2Strategic Partnerships and Collaborations
TypeLicensing Royalties
Description

Research collaborations and partnerships with pharmaceutical companies such as Novo Nordisk for MASH program and Pioneering Medicines for IBD, potentially generating milestone payments and royalties.

cellarity.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cellarity is a clinical-stage biotechnology company that discovers and develops cell state-correcting therapeutics using a proprietary multi-omics AI platform built on high-dimensional single-cell transcriptomics and deep-learning models. Its lead asset CLY-124, an oral first-in-class DCN1 inhibitor for sickle cell disease, is currently in Phase 1 clinical trials, with additional pipeline programs in myelofibrosis, MASH, and IBD executed via strategic partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 13- to 17-fold higher hit rates in drug discovery compared to industry standard approaches
+4 more records
Product overview1 text field

Cellarity is a clinical-stage biotechnology company pioneering a fundamentally new approach to drug discovery that corrects whole cell-state dysfunction to solve complex diseases. The company's proprietary platform integrates advanced transcriptomics with AI predictive modeling to discover and develop oral Cell State-Correcting therapeutics. The lead product, CLY-124 (a first-in-class DCN1 inhibitor for sickle cell disease), is in Phase 1 clinical trials. The company is also advancing programs in myelofibrosis and has partnerships with Novo Nordisk for MASH and Pioneering Medicines for IBD.

Product and service1 record
1CLY-124
CategoryInvestigational small molecule therapeutic (sickle cell disease)
Description

CLY-124 is a first-in-class oral DCN1 inhibitor and globin-switching therapy designed to increase fetal hemoglobin (HbF) early in red blood cell maturation. It is being developed for sickle cell disease and is currently in Phase 1 clinical development, with the goal of providing best-in-class HbF induction without cytotoxicity.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Strategic partnership addressing novel biologic insights in Metabolic Dysfunction-Associated Steatohepatitis (MASH). This is Cellarity's first example of a partnered program applying its disruptive approach to areas of strategic interest to a partner company. The collaboration advances Cellarity's platform application in metabolic disorders.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Research collaboration with Pioneering Medicines to develop novel, small molecule therapeutics for inflammatory bowel disease (IBD). Leverages Cellarity's platform capabilities for immune disorders.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Recursion is an AI-native drug discovery company combining high-dimensional phenomics, transcriptomics and deep learning to identify novel therapeutics. Cellarity overlaps directly on the high-dimensional transcriptomics + foundation-model approach and competes for the same pharma collaboration and talent pool.

TypeDirect peer
Description

Insitro builds ML models on patient-derived cellular data to discover and develop therapeutics for metabolic and neurological diseases. Like Cellarity, it is a privately-backed AI/ML platform biotech that partners with major pharma (e.g., Lilly, Gilead) and pursues clinical-stage assets.

TypeDirect peer
Description

Exscientia is an AI-driven precision drug design company that has multiple pharma collaborations and pipeline programs progressing through the clinic. It is directly comparable in business model (AI platform + pipeline + pharma BD) and customer base to Cellarity.

TypeDirect peer
Description

Schrödinger combines computational chemistry, physics-based modeling and ML to discover therapeutics, and licenses its platform to pharma while running an internal pipeline. Mirrors Cellarity's dual platform-plus-pipeline biotech model.

5Isomorphic Labs
TypeDirect peer
Description

Isomorphic Labs is Alphabet's AI-first drug design company building on AlphaFold and partner programs with Novartis and Lilly. Closely comparable AI-driven drug discovery approach and deal-based business model; competes for similar pharma partnerships.

TypeDirect peer
Description

Generate Biomedicines applies generative AI to design novel therapeutics across modalities. Like Cellarity, it is a US-based platform biotech founded by a top-tier life-sciences creator (Flagship Pioneering) with a multi-program pipeline and pharma partnership strategy.

TypeDirect peer
Description

AbCellera operates an AI-enabled antibody discovery platform that partners with pharma to originate programs while also advancing internal pipeline candidates. Comparable on platform-plus-pipeline model, biotech BD model, and clinical-stage ambitions.

TypeDirect peer
Description

Verge Genomics applies ML to human omics datasets (including transcriptomics) to identify drug targets and develop therapeutics for neurodegenerative diseases. Comparable AI + multi-omics platform approach, though focused on CNS indications.

TypeBroad incumbent
Description

Owkin is an AI/biopharma company using multimodal patient data and foundation models for drug discovery and diagnostics, with pharma partnerships across multiple therapeutic areas. Overlaps with Cellarity's data + AI platform narrative but spans a wider portfolio including diagnostics.

10BPGbio
TypeEmerging player
Description

BPGbio applies AI to interrogate biological pathways and develop oncology and metabolic therapeutics, with an assets-in-development pipeline. Partial overlap with Cellarity's multi-omics discovery approach and partnered-program business model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles22 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellarity

Biopharmaceuticals (Cell State-Correcting Therapeutics)cellarity.com

Cellarity is a clinical-stage biotechnology company developing oral Cell State-Correcting small molecule therapeutics through an AI-powered multi-omics and single-cell transcriptomics platform, with lead candidate CLY-124 in Phase 1 for sickle cell disease.

What Cellarity does

Cellarity is a clinical-stage biotechnology company founded in 2019 by Flagship Pioneering, headquartered in Cambridge, Massachusetts, with an additional office in Somerville, MA. The company is developing oral "Cell State-Correcting" small molecule therapeutics that aim to restore proper cell function by precisely regulating gene-switch mechanisms, rather than modulating single molecular targets as in conventional drug discovery. Its core technology is a multi-omics AI-powered discovery platform that integrates high-dimensional single-cell transcriptomics, surface receptor and chromatin accessibility data, and proprietary deep learning foundation models (including ToxPredictor for safety prediction and DrugReflector for active-learning phenotypic screening) to map disease biology and predict chemical interventions. The platform has demonstrated 13- to 17-fold higher recovery of phenotypically active compounds compared with industry-standard approaches.

Cellarity's lead asset, CLY-124, is a first-in-class DCN1 inhibitor and oral globin-switching therapeutic for sickle cell disease that entered a global Phase 1 clinical trial in June 2025 following FDA IND clearance, with 28-day proof-of-concept data expected in Q4 2026. The pipeline additionally includes a JAK2V617F-selective program for myelofibrosis and partnered programs with Novo Nordisk in MASH and with Pioneering Medicines in inflammatory bowel disease. The company is pre-revenue, monetizes through eventual product sales and/or licensing/royalty arrangements with pharmaceutical partners, and has raised $274 million in total funding, most recently a $121 million Series C in October 2022 led by Flagship Pioneering with participation from Kyowa Kirin and Hanwha Impact Partners.

Cellarity firmographics

Firmographics
Name
Cellarity
Legal name
Cellarity, Inc.
Website
https://cellarity.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Cellarity is a clinical-stage biotechnology company developing oral Cell State-Correcting small molecule therapeutics through an AI-powered multi-omics and single-cell transcriptomics platform, with lead candidate CLY-124 in Phase 1 for sickle cell disease.
Ownership category
akta.pro rank

Cellarity industry classification

Industry
Product category
Biopharmaceuticals (Cell State-Correcting Therapeutics)
akta.pro industry
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Cell state therapeutics
  • AI drug discovery
  • Multi-omics platform
  • Small molecule therapeutics
  • Transcriptomics biotechnology

Where Cellarity is headquartered

Location

Headquarters

HQ city
Somerville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Cellarity business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical stage company developing novel therapeutics. Revenue will be generated through eventual product sales following regulatory approval, with potential licensing or partnership arrangements with pharmaceutical companies for development and commercialization rights.
  2. Strategic Partnerships and Collaborations: Research collaborations and partnerships with pharmaceutical companies such as Novo Nordisk for MASH program and Pioneering Medicines for IBD, potentially generating milestone payments and royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Cellarity product offering

Product offering

Core offering

Cellarity is a clinical-stage biotechnology company that discovers and develops cell state-correcting therapeutics using a proprietary multi-omics AI platform built on high-dimensional single-cell transcriptomics and deep-learning models. Its lead asset CLY-124, an oral first-in-class DCN1 inhibitor for sickle cell disease, is currently in Phase 1 clinical trials, with additional pipeline programs in myelofibrosis, MASH, and IBD executed via strategic partnerships.

Product overview

Cellarity is a clinical-stage biotechnology company pioneering a fundamentally new approach to drug discovery that corrects whole cell-state dysfunction to solve complex diseases. The company's proprietary platform integrates advanced transcriptomics with AI predictive modeling to discover and develop oral Cell State-Correcting therapeutics. The lead product, CLY-124 (a first-in-class DCN1 inhibitor for sickle cell disease), is in Phase 1 clinical trials. The company is also advancing programs in myelofibrosis and has partnerships with Novo Nordisk for MASH and Pioneering Medicines for IBD.

Differentiator

Problem solved

Functional benefit

Products and services

  • CLY-124 CLY-124 is a first-in-class oral DCN1 inhibitor and globin-switching therapy designed to increase fetal hemoglobin (HbF) early in red blood cell maturation. It is being developed for sickle cell disease and is currently in Phase 1 clinical development, with the goal of providing best-in-class HbF induction without cytotoxicity.

Quantifiable outcome

  • 13- to 17-fold higher hit rates in drug discovery compared to industry standard approaches
  • +4 more outcomes

Companies that use Cellarity

Customer profile

Segments4 records

Ideal customer profiles2 records

Cellarity technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Cellarity partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered major.

  • Novo NordiskmajorStrategic or Co-development PartnerStrategic partnership addressing novel biologic insights in Metabolic Dysfunction-Associated Steatohepatitis (MASH). This is Cellarity's first example of a partnered program applying its disruptive approach to areas of strategic interest to a partner company. The collaboration advances Cellarity's platform application in metabolic disorders.
  • Pioneering MedicinesmajorStrategic or Co-development PartnerResearch collaboration with Pioneering Medicines to develop novel, small molecule therapeutics for inflammatory bowel disease (IBD). Leverages Cellarity's platform capabilities for immune disorders.

Scale indicators5 records

Recent moves8 records

Expansion highlights4 records

Cellarity competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: Recursion is an AI-native drug discovery company combining high-dimensional phenomics, transcriptomics and deep learning to identify novel therapeutics. Cellarity overlaps directly on the high-dimensional transcriptomics + foundation-model approach and competes for the same pharma collaboration and talent pool.
  • Insitro: Insitro builds ML models on patient-derived cellular data to discover and develop therapeutics for metabolic and neurological diseases. Like Cellarity, it is a privately-backed AI/ML platform biotech that partners with major pharma (e.g., Lilly, Gilead) and pursues clinical-stage assets.
  • Exscientia: Exscientia is an AI-driven precision drug design company that has multiple pharma collaborations and pipeline programs progressing through the clinic. It is directly comparable in business model (AI platform + pipeline + pharma BD) and customer base to Cellarity.
  • Schrödinger: Schrödinger combines computational chemistry, physics-based modeling and ML to discover therapeutics, and licenses its platform to pharma while running an internal pipeline. Mirrors Cellarity's dual platform-plus-pipeline biotech model.
  • Isomorphic Labs: Isomorphic Labs is Alphabet's AI-first drug design company building on AlphaFold and partner programs with Novartis and Lilly. Closely comparable AI-driven drug discovery approach and deal-based business model; competes for similar pharma partnerships.
  • Generate Biomedicines: Generate Biomedicines applies generative AI to design novel therapeutics across modalities. Like Cellarity, it is a US-based platform biotech founded by a top-tier life-sciences creator (Flagship Pioneering) with a multi-program pipeline and pharma partnership strategy.
  • AbCellera Biologics: AbCellera operates an AI-enabled antibody discovery platform that partners with pharma to originate programs while also advancing internal pipeline candidates. Comparable on platform-plus-pipeline model, biotech BD model, and clinical-stage ambitions.
  • Verge Genomics: Verge Genomics applies ML to human omics datasets (including transcriptomics) to identify drug targets and develop therapeutics for neurodegenerative diseases. Comparable AI + multi-omics platform approach, though focused on CNS indications.

Broad incumbents

  • Owkin: Owkin is an AI/biopharma company using multimodal patient data and foundation models for drug discovery and diagnostics, with pharma partnerships across multiple therapeutic areas. Overlaps with Cellarity's data + AI platform narrative but spans a wider portfolio including diagnostics.

Emerging players

  • BPGbio: BPGbio applies AI to interrogate biological pathways and develop oncology and metabolic therapeutics, with an assets-in-development pipeline. Partial overlap with Cellarity's multi-omics discovery approach and partnered-program business model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Cellarity social profiles

Digital presence

Cellarity financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellarity leadership team

Management profile

Number of profiles

Profiles22 records

Cellarity funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellarity M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellarity

What does Cellarity do?

Cellarity is a clinical-stage biotechnology company that discovers and develops cell state-correcting therapeutics using a proprietary multi-omics AI platform built on high-dimensional single-cell transcriptomics and deep-learning models. Its lead asset CLY-124, an oral first-in-class DCN1 inhibitor for sickle cell disease, is currently in Phase 1 clinical trials, with additional pipeline programs in myelofibrosis, MASH, and IBD executed via strategic partnerships.

Is Cellarity a public or private company?

Cellarity is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cellarity founded?

Cellarity was founded in 2019. It employs 51 to 100 people.

Where is Cellarity based?

Cellarity is headquartered in Somerville, United States, in the North America region.

How does Cellarity make money?

Two revenue lines are on record. Drug Development and Commercialization is the primary driver. The others are strategic Partnerships and Collaborations.

Who are Cellarity's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Insitro, Exscientia, Schrödinger, Isomorphic Labs, Generate Biomedicines, AbCellera Biologics and Verge Genomics. Owkin is listed as a broad incumbent. BPGbio is listed as an emerging player.

Does Cellarity have an API?

No public API is recorded for Cellarity.

What industry is Cellarity in?

Cellarity's product category is Biopharmaceuticals (Cell State-Correcting Therapeutics). Its primary akta.pro industry code is HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterFlagship merges three platform companies into AI-driven drug discovery firm EtceleraFlagship Pioneering formed Etcelera by merging the platforms of Cellarity, Etiome, and Empress Therapeutics. The company aims to build "causal intelligence" in human biology, determining what drives disease and predicting drug effects before clinical trials.BioPharma DiveFlagship blends three biotech startups to form EtceleraFlagship Pioneering merged three biotech startups—Etiome, Cellarity, and Empress Therapeutics—into Etcelera, led by Adrian Rawcliffe. The company combines AI with drug discovery tools to predict successful medicines, targeting hematological, immune, and metabolic-fibrotic disorders. No new funding was announced, but the merged entities had raised $374 million in venture capital.YahooFlagship blends three biotech startups to form EtceleraFlagship Pioneering merged three of its portfolio companies—Etiome, Cellarity, and Empress Therapeutics—into Etcelera Therapeutics, led by Adrian Rawcliffe. The new venture combines AI with drug discovery tools to predict which experimental medicines might succeed in clinical trials. It aims to use perturbation data to gauge drug failure risk.The Tufts DailyTufts Biotechnology Series: Ted Myles, a leading voice in biotech, shares his experiences with Tufts studentsTed Myles, CEO of Cellarity, spoke at Tufts University's School of Engineering Biotechnology Industry Series, sharing his career journey from finance to biotech leadership, including his experience managing a crisis at Advanced Cell Technology. He discussed lessons on ethical decision-making, accountability, transparency, and the importance of mentorship when navigating challenges in the biotechnology industry. The article frames his insights as valuable perspective for engineering students looking to apply their coursework beyond academia.BioSpaceCellarity Presents on Cell State-Correcting Pipeline Programs for Sickle Cell Disease and Myelofibrosis at 2025 American Society of Hematology Annual MeetingCellarity presented preclinical data on its investigational therapies for sickle cell disease and myelofibrosis at the 2025 American Society of Hematology Annual Meeting. The company highlighted CLY-124, a lead asset currently in Phase 1 clinical trials, which demonstrated superiority to hydroxyurea in inducing fetal hemoglobin without cytotoxicity.Business Wire BlogCellarity Presents on Cell State-Correcting Pipeline Programs for Sickle Cell Disease and Myelofibrosis at 2025 American Society of Hematology Annual MeetingCellarity, a clinical-stage biotechnology company, presented new preclinical data on its investigational programs for sickle cell disease and myelofibrosis at the 2025 American Society of Hematology Annual Meeting. The company's lead asset CLY-124, a first-in-class DCN1 inhibitor for sickle cell disease, demonstrated superiority to hydroxyurea in preclinical studies with no dose-limiting toxicities and is currently advancing through a Phase 1 dose-escalating study in healthy volunteers and adults with sickle cell disease. Cellarity also presented findings on selective JAK2 targeting for myelofibrosis using its AI-powered transcriptomics platform, with candidates showing potential to avoid anemia commonly associated with existing therapies.PharmiWeb.comCellarity Presents on Cell State-Correcting Pipeline Programs for Sickle Cell Disease and Myelofibrosis at 2025 American Society of Hematology Annual MeetingCellarity, a clinical-stage biotech company headquartered in Somerville, Massachusetts, presented preclinical data at the 2025 American Society of Hematology Annual Meeting on its investigational programs for sickle cell disease and myelofibrosis. The company's lead asset CLY-124, a first-in-class oral DCN1 inhibitor for globin-switching therapy, demonstrated superiority to hydroxyurea in preclinical studies by inducing fetal hemoglobin without cytotoxicity, and is currently in Phase 1 dose-escalation trials. Cellarity also disclosed progress on a myelofibrosis program leveraging AI-driven transcriptomics to identify small molecule candidates that selectively suppress JAK2-mutant cells while sparing normal hematopoiesis, addressing a common side effect limitation of existing therapies.GenengnewsCellarity’s AI Model Improves Drug Safety by Predicting Liver InjuryCellarity, a Somerville-based clinical-stage biotech founded by Flagship Pioneering in 2019, has developed an AI model called ToxPredictor that predicts drug-induced liver injury (DILI) by evaluating toxicogenomics data through its DILImap transcriptomics library of 300 compounds. The model demonstrated 88% sensitivity at 100% specificity in validation testing and successfully identified multiple Phase III clinical safety failures that had gone undetected in animal studies, potentially saving pharmaceutical companies an estimated $350 million annually per company. Cellarity has released ToxPredictor and its validation data as open-source for non-commercial use, with the company's first drug candidate CLY-124 currently undergoing Phase I clinical trials.BioSpaceCellarity Publishes Groundbreaking Framework for Predicting Drug Safety in Nature CommunicationsCellarity, a clinical-stage biotechnology company, published a manuscript in Nature Communications describing ToxPredictor, an AI-powered framework for predicting drug-induced liver injury (DILI) built on a toxicogenomics library of 300 compounds called DILImap. The framework demonstrated 88% sensitivity at 100% specificity in blind evaluation, outperforming over 20 industry-standard preclinical safety models and identifying numerous phase 3 clinical safety failures missed by animal studies. The company has made the model and validation data publicly available as open-source to enable broader collaboration and a paradigm shift in safety evaluations.